Study: GSK's Avodart significantly reduces prostate cancer risk

04/27/2009 | NYTimes.com

A large clinical study showed that, after four years of observation, the risk of all biopsy-detectable prostate cancer was 23% lower in male patients given GlaxoSmithKline's Avodart compared with those who received placebo. The trial, which focused on 8,100 men ages 50 to 75 with high levels of prostate-specific antigen, could boost GSK's chances of obtaining approval for Avodart's expanded use.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA